XOMA (XOMA)
(Delayed Data from NSDQ)
$24.78 USD
-0.66 (-2.59%)
Updated May 3, 2024 04:00 PM ET
After-Market: $25.10 +0.32 (1.29%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
XOMA 24.78 -0.66(-2.59%)
Will XOMA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for XOMA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for XOMA
Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Misses Revenue Estimates
Xoma (XOMA) Moves 7.7% Higher: Will This Strength Last?
XOMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates
Strength Seen in Vertex (VRTX): Can Its 5.0% Jump Turn into More Strength?
Xoma (XOMA) Reports Q3 Loss, Misses Revenue Estimates
Other News for XOMA
Biotech Alert: Searches spiking for these stocks today
Analysts Are Bullish on These Healthcare Stocks: Exelixis (EXEL), Cyclo Therapeutics (CYTH)
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATOâ„¢ (clindamycin phosphate) Vaginal Gel 2%
Xoma acquires economic interest in three assets from Dare Bioscience
Dare Bioscience secures $22M in non-dilutive strategic royalty financing